This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Protease activated receptor 2 and epidermal growth factor
receptor are involved in the regulation of human sperm motility
Karina Zitta1, Martin
Albrecht2, Stephan
Weidinger1, Artur
Mayerhofer2, Frank Köhn1
1Department of Dermatology and Allergy, Technical University Munich, Biedersteiner Strasse 29, Munich 80802, Germany
2Institute of Anatomy, Ludwig-Maximilians-University, Biedersteiner Strasse 29, Munich 80802, Germany
Abstract
Aim: To investigate mechanisms of tryptase-induced reduction of sperm motility and explore whether epidermal
growth factor receptor (EGF-R) and protease activated receptor 2 (PAR-2)- associated pathways are
involved. Methods: Fresh semen was collected from healthy donors
(n = 15). Semen parameters and quality were assessed in
accordance with the World Health Organization (WHO) criteria. Swim-up sperm were fixed and subjected to
immunocytochemistry and immunoelectronmicroscopy with specific antibodies directed against PAR-2 and EGF-R. Protein
extractions from swim-up spermatozoa were analyzed by Western blotting with antibodies for both receptors.
Motility of spermatozoa was evaluated by computer-assisted semen analysis.
Results: Immunocytochemistry found PAR-2 and EGF-R in approximately 30% of examined human ejaculated spermatozoa. Both receptors were localized
in the plasma membrane. Like tryptase, the PAR-2 synthetic agonist SLIGKV reduced sperm motility, and this effect
was inhibited by application of two specific EGF-R pathway blockers (AG1478 and
PD168393). Conclusion: The observed reduction of sperm motility by tryptase through the PAR-2 receptor involves EGF-R
pathways. (Asian J Androl 2007 Sep; 9: 690_696)
Keywords: spermatozoa; motility; epidermal growth factor receptor; protease activated receptor
Correspondence to: Dr Karina Zitta, Ludwig-Maximilians-University Munich, Institute for Molecular Animal Breeding, Moorversuchsgut, Hackerstrasse
27, 85764 Oberschleibheim, Germany.
Tel: +49-89-2180-78442 Fax: +49-89-2180-78402
E-mail: K.Zitta@gen.vetmed.uni-muenchen.de
Received 2006-10-13 Accepted 2007-04-04
DOI: 10.1111/j.1745-7262.2007.00289.x
1 Introduction
Mast cells (MC) are located throughout the male and female genital tract and secrete a plethora of potent
mediators [1_3]. Although their function in reproduction is largely unknown, the importance of MC secretory products is
indicated by clinical studies showing improved semen parameters after treating subfertile and infertile men with MC
blockers [4_6].
The main MC product, the serine protease tryptase, is of special interest and has been described as elevated in the
seminal plasma of infertile subjects [3]. Tryptase has been shown to exert action through activation of the
protease-activated receptor 2 (PAR-2) [7_9], but other
models of action suggest an activation of phosphatidylinositol 3-kinases
proteolytically independently from PAR-2 [10].
PAR-2 belongs to the family of G protein-coupled receptors with seven transmembrane-spanning domains,
comprising four members, known as PAR-1, PAR-2, PAR-3 and PAR-4 [11]. PAR-2 can be activated by multiple
trypsin-like enzymes, including trypsin, and MC tryptase. The
mechanism of activation of this receptor is the
irreversible proteolytic cleavage of the N-terminal external
domain of the protein. The newly generated N-terminus
serves as a tethered ligand capable to activate the
receptor itself. Synthetic activating peptides, like SLIGKV,
which mimic the tethered ligand of PAR-2, specifically
activate PAR-2 independently of receptor proteolysis [11].
In our recent studies, we localized PAR-2 in the plasma
membrane of human spermatozoa and found that
activation of PAR-2 receptors by human recombinant tryptase
reduced human sperm motility in a dose-dependent and
time-dependent fashion involving MAP-kinases [3, 12].
Epidermal growth factor (EGF) is also present in
seminal fluid [13] and some authors have observed an
effect of the molecule on several sperm motility
parameters [14]. Interestingly, Darmoul
et al. [15] described a novel pathway in which MAP kinase activation is linked
to EGF-R transactivation, raising the question of whether
such interactions might also occur in human spermatozoa.
Here, we show that PAR-2 and EGF-R are both localized on human spermatozoa. Specific activation of
PAR-2 using a selective agonist peptide in
vitro leads to a decrease in sperm motility, which can be blocked by
application of inhibitors of EGF-R pathways, pointing
towards the involvement of EGF-R in PAR-2 mediated
inhibition of human sperm motility.
2 Materials and methods
2.1 Chemicals
Human tubal fluid medium (HTFM) based on Earle's
balanced solution containing 26 mmol/L sodium
bicarbonate, 0.8 mmol/L sodium pyruvate, 2.8 mmol/L
glucose, 1 mL/L synthetic serum replacement SSR, 1%
human serum albumine, 15 mmol/L HEPES, 50 000 IU/L
penicillin-G, 50 mg/L streptomycin sulphate and
0.01 g/L (pH 7.3) phenol red were all obtained from Stephan Gück
GmbH (Berlin, Germany). The following were used: SLIGKV (peptide PAR-2 agonist; NeoMPS, Strasbourg,
France), AG1478 (EGF-R tyrosine kinase-specific inhibitor; Calbiochem, Bad Soden, Germany), PD168393
(EGF-R tyrosine kinase-specific inhibitor; Calbiochem,
Bad Soden, Germany) and recombinant EGF (Sigma-Aldrich, Schnelldorf, Germany). Antibodies were
purchased from the following vendors: polyclonal
anti-human EGF-R and the respective blocking peptide from Dunn
Labortechnik GmbH (Asbach, Germany); polyclonal
anti-human PAR-2 from Lifespan Biosciences (Seattle, WA,
USA); and monoclonal anti-human PAR-2 from Invitrogen GmbH (Karlsruhe, Germany). The
secondary antibodies for immunofluorescence were coupled
to fluorescein isothiocyanate (FITC) or tetramethyl
rhodamine isothiocyanate (TRITC). For Western blots,
the secondary antibodies were coupled to peroxidase.
2.2 Sperm preparation
Fresh semen was collected from healthy donors
(n = 15) with no history of diseases related to infertility
and who had given informed consent. Semen samples
were allowed to liquefy at room temperature for 30 min,
then they were washed twice (500 × g, 10 min) and the
pellet was resupended in 2 mL of HTFM medium. After
1 h at 37ºC, the swim-up sperm [16], in concentrations
of 1_2 × 107 cells/mL, were analyzed. Semen
parameters and quality were assessed in accordance with World
Health Organization (WHO) criteria [17]. Motile
spermatozoa were evaluated by computer-assisted semen
analysis (CASA) using the Stroemberg_Mika cell motion
analyzer (version 4.4; Mika Medical GmbH, Rosenheim,
Germany). Briefly, 5 µL aliquots of sperm suspensions
were transferred into disposable counting chambers
(10 µm depth). Measurements of motility parameters
were performed and observed by a high resolution
CCD-video camera and an Optiphot-2 microscope (Nikon,
Tokyo, Japan). A minimum of 100 spermatozoa from at
least 10 different fields were analyzed. The motility was
graded as follows: classes a and b, fast and weak
forward motility; class c, no progressive motility; and class
d, immobile spermatozoa. Sperm velocity and kinematics
characteristics were evaluated only for motile sperm and
expressed as mean values of straight progressive
velocity (a + b). Sperm vitality was assessed using Eosin
staining. For motility experiments, sperm were incubated
with: SLIGKV (100 µmol/L), AG1478
(10 µmol/L) or PD168393 (2 µmol/L) and a combination of the blockers
with SLIGKV peptide. The samples were collected and
measured after 60 min. Motility results reported in the
present study represent percentage of motility (WHO a +
b) normalized to the control group considered as
100%.
2.3 Statistical analysis
All results were normalized to their respective
controls, considered as 100%, and expressed as the
average percentage of motility ± SEM of 3_12 experiments.
Results were analyzed statistically by using the computer
program PRISM (GraphPad, San Diego, CA, USA). To assume normal distribution, all data were subjected to
arcsine square root transformation. Statistical analysis
was performed using parametric tests. Comparison
between columns was performed with analysis of variance
and the Tukey post test. Values with
P < 0.05 compared with control were considered statistically significant.
2.4 Immunoelectronmicroscopy
Gold-immunoelectronmicroscopy for EGF-R was performed on ejaculated spermatozoa (fixed in 4%
paraformaldehyde, 0.1% glutaraldehyde in 0.05 mol/L
phosphate-buffered saline [PBS], pH 7.4) using Lowicryl
(K4M; Polysciences, Eppenheim, Germany) with goat anti-EGF-R polyclonal antibodies and a secondary
gold-labelled (10 nm) antibody (1:20; Aurion, Wageningen, The
Netherlands). Electron microscopy was performed with
a Zeiss Electron microscope EM10 using a previously
described method [3, 18]. For control purposes, the
antiserum was omitted or replaced with normal rabbit
serum.
2.5 Immunocytochemistry
Indirect immunofluorescence was performed on swim-up sperm. Briefly, 500 µL of swim-up sperm were
fixed with 500µL of 4% paraformaldehyde for 5 min,
washed twice with PBS (500 × g, 5 min) and resuspended
to yield 1 000 000 cells/mL. Drops of this solution were
placed on cover slips previously coated with 20 µg/mL
of polylysine and air-dried. Specimens were re-hydrated
and unspecific binding was blocked using 2% goat or
donkey serum. Slides were incubated with the first
antibody at 4ºC overnight (EGF-R 1:100 and PAR-2 1:250).
Later, they were rinsed in saline solution (three times at
room temperature) and re-incubated for 1 h with second
antibody coupled with FITC or TRITC. Slides were rinsed in saline solution and mounted with glycerin for
fluorescence microscope examination (Zeiss Axiomat,
Jena, Germany).
Fixed and immobilized spermatozoa (described above)
were incubated with fluoresceinated Pisum Sativum lectin, to check whether the fixation procedure and
manipulation induced membrane rupture.
2.6 Protein extraction and Western blot
Swim-up sperm were washed twice with PBS and the pellet was resuspended in sample buffer to yield
2 000 000 total cells/10 µL. We performed immunoblots,
as described by Frungieri et al. [19], using a mouse
monoclonal antibody against human PAR-2 (1:250) and
a polyclonal antibody anti-human EGF-R (1:100). For
EGF-R blockage we incubated the polyclonal anti-human EGF-R antibody (2 µg/mL, dilution 1:100) together
with blocking peptide (20 µg/mL). The secondary
antibodies were coupled to peroxidase and developed with
chemiluminescent substrate (PiercePierce, Rockford, IL,
USA), as described previously [19].
3 Results
3.1 PAR-2 and EGF-R-like determinants are present on
human spermatozoa
As a prerequisite for a possible crosstalk between
PAR-2 and EGF-R, we investigated whether these two
receptors are present on swim-up sperm. In Western
blots, specific antibodies indicated the presence of both
receptors. The PAR-2 protein had an expected
molecular weight of 50 kDa [20]. The EGF-R protein displayed
a size of 85 kDa, which was lower than the expected
molecular weight of 170 kDa. To test the specificity of
the antibody signal, we blocked the EGF-R antibody with
a specific peptide. The absence of a band under these
conditions suggests that the antibody recognizes a
possibly truncated EGF-R protein on human sperm extracts
(Figure 1).
The presence of PAR-2 and EGF-R was also indicated by immunocytochemistry on swim-up
spermatozoa (Figure 2A). Immunocolocalization for both
receptors showed the presence of PAR-2 and EGF-R (Figure
2B) in approximately 30% of the sperm cells.
Localization of PAR-2 in the plasma membrane has
been shown by our group previously [3]. By using immunoelectronmicroscopy, we now also localize the
EGF-R in the plasma membrane of ejaculated human spermatozoa (Figure 3).
3.2 EGF-R blockage inhibits the PAR-2 mediated
effect on human sperm motility
Having established the presence of both receptors
on human sperm, we investigated whether PAR-2 mediated effects on sperm motility could be altered by
inhibiting EGF-R intracellular pathways. The stimulation of
spermatozoa with the PAR-2 agonist peptide SLIGKV resulted in a significant decrease of motility (range:
74%_86% compared to control; see Figure 4 for two sets of
experiments) after 60 min, as measured by CASA. This
confirmed our previously published results on the effect
of human recombinant tryptase on human sperm motility [3]. Compared to tryptase, which as serine protease
might exert various and so far undetermined effects on
human sperm, SLIGKV is a selective PAR-2 agonist.
Therefore, our results show, for the first time, that the
reduction of human sperm motility is indeed a result of
activation of PAR-2.
Incubation of spermatozoa with SLIGKV in the
presence of two different and specific EGF-R inhibitors
(AG1478 and PD168393) reverted the SLIGKV effect on sperm motility to control values (motility [% of
control]: SLIGKV = 86.50% ± 4.05%; SLIGKV +
AG1478 = 107.29% ± 3.83% [Figure 4A]; SLIGKV =
74.15% ± 4.48%; SLIGKV + PD168393 = 92.02% ±
7.27% [Figure 4B]). Inhibitors alone had no effect on
motility (data not shown).
4 Discussion
The present study extends previous work by showing
that PAR-2 on human sperm can be activated by SLIGKV
peptide [12]. In addition, we found that PAR-2 and
EGF-R are both present on human sperm and report that
EGF-R pathway blockers inhibit the inhibitory effect of PAR-2
action on human sperm motility.
Western blot studies revealed that PAR-2 in human
sperm had the expected size of 50 kDa, whereas EGF-R
showed a signal at 85 kDa. The most common form of
the EGF-R is a 170-kDa transmembrane glycoprotein [21], but a variety of EGF-R forms with wide range of
molecular weights have also been described. This might
be a result of differences in the glycosylation pattern of
the receptor in different cell types or possible truncation
of the protein.
EGF-R has previously been described in human sperm
by other authors [14, 21_23]. Our dual-labeling studies
using specific antibodies showed that at least 30% of the
cells coexpressed EGF-R and PAR-2; in addition, immunoelectronmicroscopy indicates that PAR-2 [3] and
EGF-R (the present study) are located in the human sperm
membrane.
The functions of EGF in the male reproductive tract
are still not very well established. Because EGF is present
in seminal fluid [13, 24] it could alter sperm function.
This is suggested by Naz and Kaplan [14], who showed
that incubation of sperm with various amounts of EGF
for 7_8 h enhances sperm motility. Moreover, animal
in vivo experiments showed that the administration of EGF
can improve epididymal sperm content and motility [25].
Our studies with recombinant EGF at a concentration of
60 nmol/L did not reveal any alteration of sperm motility
(data not shown), which might be explained by the fact
that in contrast to the experimental settings used by Naz
and Kaplan [14], we incubated the sperm for a shorter
period.
In addition to our previous studies, where tryptase
reduced sperm motility, our results obtained with the
specific PAR-2 agonist peptide SLIGKV confirm the
specificity of PAR-2 activation. This is of importance because
tryptase, besides activating PAR-2, might also exert other
currently unknown proteolytic effects, whereas SLIGKV
only acts on PAR-2 and specifically inhibited human sperm
motility. This is the first report showing clearly that the
tryptase effect on human sperm motility is a result of
PAR-2 activation and not to any other proteolytic products that
might be generated by tryptase.
To investigate whether EGF-R associated signal transduction events might contribute to sperm motility
we used SLIGKV to activate PAR-2, and two different
specific EGF-R tyrosine kinase inhibitors (AG1478 and
PD168393) to block EGF-R mediated signal transduction.
Importantly, the blockage of EGF-R upon PAR-2 stimulation by SLIGKV reverted the impairment of sperm
motility induced by SLIGKV alone. This clearly implies
the contribution of both receptors to this effect and also
suggests an interaction of their signaling pathways.
Therefore, we conclude that the novel mechanism of
receptor crosstalk, first described for other cell types,
also occurs in human sperm [15].
The mechanisms by which the two receptors can share signaling pathways are still far from being
understood. In particular, the fact that human
spermatozoa can display a high compartmentalization leads to
the question of how this barrier is bypassed by signal
transduction events.
The localization of PAR-2 and EGF-R in ejaculated
sperm might hint to other events as well. Whether, for
example, it might also participate in the acrosomal
reaction, needs to be evaluated in future studies.
In summary, our data demonstrate that PAR-2
activation in human spermatozoa leads to signaling events
that result in a reduction of sperm motility by utilizing
EGF-R-associated signal transduction pathways.
Aknowledgment
This work was supported in part by a grant from
Deutsche Forschungsgemeinschaft MA1080/16-1 and by
a fellowship from Deutscher Akademischer Austausch-
dienst to Dr Karina Zitta. We thank Gabriele Terfloth for
excellent technical assistance.
References
1 Meineke V, Frungieri MB, Jessberger B, Vogt H, Mayerhofer
A. Human testicular mast cells contain tryptase: increased
mast cell number and altered distribution in the testes of
infertile men. Fertil Steril 2000; 74: 239_44.
2 Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev
1997; 77: 1033_79.
3 Weidinger S, Mayerhofer A, Frungieri MB, Meineke V, Ring
J, Kohn FM. Mast cell-sperm interaction: evidence for tryptase
and proteinase-activated receptors in the regulation of sperm
motility. Hum Reprod 2003; 18: 2519_24.
4 Cavallini G. Male idiopathic oligoasthenoteratozoospermia.
Asian J Androl 2006; 8: 143_57.
5 Schill WB, Schneider J, Ring J. The use of ketotifen, a mast
cell blocker, for treatment of oligo- and asthenozoospermia.
Andrologia 1986; 18: 570_3.
6 Yamamoto M, Hibi H, Miyake K. New treatment of
idiopathic severe oligozoospermia with mast cell blocker: results
of a single-blind study. Fertil Steril 1995; 64: 1221_3.
7 Akers IA, Parsons M, Hill MR, Hollenberg MD, Sanjar S,
Laurent GJ, et al. Mast cell tryptase stimulates human lung
fibroblast proliferation via protease-activated receptor-2. Am
J Physiol Lung Cell Mol Physiol 2000; 278: L193_201.
8 Gruber BL, Kew RR, Jelaska A, Marchese MJ, Garlick J, Ren
S, et al. Human mast cells activate fibroblasts: tryptase is a
fibrogenic factor stimulating collagen messenger ribonucleic
acid synthesis and fibroblast chemotaxis. J Immunol 1997;
158: 2310_7.
9 Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y.
Role of mast cell tryptase in renal interstitial fibrosis. J Am
Soc Nephrol 2001; 12: 1668_76.
10 Brown JK, Hollenberg MD, Jones CA. Tryptase activates
phosphatidylinositol 3-kinases proteolytically independently
from proteinase-activated receptor-2 in cultured dog airway
smooth muscle cells. Am J Physiol Lung Cell Mol Physiol
2006; 290: L259_69.
11 Hollenberg MD, Compton SJ. International Union of
Pharmacology. XXVIII. Proteinase-activated receptors.
Pharmacol Rev 2002; 54: 203_17.
12 Weidinger S, Mayerhofer A, Kunz L, Albrecht M, Sbornik M,
Wunn E, et al. Tryptase inhibits motility of human
spermatozoa mainly by activation of the mitogen-activated protein
kinase pathway. Hum Reprod 2005; 20: 456_61.
13 Kishi H, Ishibe T, Usui T, Miyachi Y. Epidermal growth
factor (EGF) in seminal plasma and prostatic gland: a
radioreceptor assay. Arch Androl 1988; 20: 243_9.
14 Naz RK, Kaplan P. Effects of epidermal growth factor on
human sperm cell function. J Androl 1993; 14: 240_7.
15 Darmoul D, Gratio V, Devaud H, Laburthe M.
Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK
phosphorylation and cell proliferation are mediated by
epidermal growth factor receptor transactivation. J Biol Chem
2004; 279: 20927_34.
16 Ausmanas M, Tureck RW, Blasco L, Kopf GS, Ribas J,
Mastroianni L Jr. The zona-free hamster egg penetration
assay as a prognostic indicator in a human in
vitro fertilization program. Fertil Steril 1985; 43: 433_7.
17 World Health Organization. WHO Laboratory Manual for
Examination of Human Semen and Semen_Cervical Mucus
Interactions. New York: Cambridge University Press, 1999.
18 Mayerhofer A, Hohne-Zell B, Gamel-Didelon K, Jung H,
Redecker P, Grube D, et al. Gamma-aminobutyric acid
(GABA): a para- and/or autocrine hormone in the pituitary.
FASEB J. 2001; 15: 1089_91.
19 Frungieri MB, Albrecht M, Raemsch R, Mayerhofer A. The
action of the mast cell product tryptase on cyclooxygenase-2
(COX2) and subsequent fibroblast proliferation involves
activation of the extracellular signal-regulated kinase isoforms 1
and 2 (erk1/2). Cell Signal 2005; 17: 525_33.
20 Gruber BL, Marchese MJ, Santiago-Schwarz F, Martin CA,
Zhang J, Kew RR. Protease-activated receptor-2 (PAR-2)
expression in human fibroblasts is regulated by growth factors and
extracellular matrix. J Invest Dermatol 2004; 123: 832_9.
21 Damjanov I, Solter D, Knowles BB. Functional epidermal
growth factor receptor localizes to the postacrosomal region
of human spermatozoa. Biochem Biophys Res Commun 1993;
190: 901_6.
22 Erdogru T, Gulkesen KH, Bahceci M, Karpuzoglu G, Baykara
M. The role of expression of extracellular matrix proteins and
epidermal growth factor receptor activity on fertilization
capacity of testicular harvested spermatozoa. Andrologia 2002;
34: 98_106.
23 Markova MD, Marinova TT. EGF receptor-like
determinants on human spermatozoa and their possible cytoskeletal
association. Folia Biol (Praha) 1999; 45: 143_5.
24 Richards RC, Lewis-Jones DI, Walker JM, Desmond AD.
Epidermal growth factor (urogastrone) in human seminal
plasma from fertile and infertile males. Fertil Steril 1988; 50:
640_3.
25 Cheng D, Zheng XM, Li SW, Yang ZW, Hu LQ. Effects of
epidermal growth factor on sperm content and motility of rats
with surgically induced varicoceles. Asian J Androl. 2006; 8:
713_7.
|